What Does Shire Mexico Have to Say About Orphan Drugs?
Raul Vivar, General Director of Shire Mexico, will be speaking at this year’s BioPharma Mexico. Raul’s presentation is titled “Accessing public institutions: A success story changing the lives of lysosomal disease patients”, and will take place at 4:05 pm on Wednesday, November 5th. Don’t miss it!
During his presentation, Raul will answer the questions:
• How does an orphan drug get into the basic formulary for a government health institution?
• What is the impact of regulation for orphan drugs on rare disease patients?
• How has Shire been successful in Mexico?
Can’t wait until the conference?
No problem! We had the pleasure to interview Raul before the event and asked him various questions regarding the status of orphan drugs in Mexico that give many valuable insights into the workings of the industry. I hope you enjoy it, and if you have any questions or comments, please don’t hesitate to get in touch.
Shire focuses on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Their two strategic priorities are to drive optimum performance of their existing products, enabling access to these medicines for patients today and building their pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients.
BioPharma Mexico brings together COFEPRIS, government, payers, biopharma, biotech and academia to talk about strategies to bring biocomparables, stem cells and orphan drugs to market faster. If you’re looking to expand into Mexico, BioPharma Mexico is definitely the event you cannot afford to miss.
Image courtesy of BioPharma Mexico 2014. The Orphan Druganaut Blog is a Media Partner.
Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.